Skip to main content

Table 1 Clinicopathalogical variables in TACE+RFA group and TACE alone group

From: Transcatheter arterial chemoembolization combined with radiofrequency ablation delays tumor progression and prolongs overall survival in patients with intermediate (BCLC B) hepatocellular carcinoma

Variables

TACE

TACE+RFA

P value

n = 156

n = 55

Gender

Male

138(88.5%)

47(85.4%)

0.56

Female

18(11.5%)

8(14.6%)

 

Age (years)

<=50

54(34.6%)

19(34.6%)

0.99

>50

102(65.4%)

36(66.4%)

 

HBsAg

Positive

118(75.6%)

36(65.5%)

0.14

Negative

38(24.4%)

19(34.5%)

 

Child-Pugh grade

A

136(87.2%)

48(87.3%)

0.98

B

20(12.8%)

7(12.7%)

 

AFP (ug/L)

Positive >20

108(69.2%)

36(65.5%)

0.61

Negative <=20

48(30.8%)

19(34.5%)

 

Tumor number

Single

115(73.7%)

35(66.2%)

0.30

Multiple

41(26.3%)

20(33.8%)

 

*Tumor size

Medial (range, cm)

6.0(5–8)

5.9(5–8)

0.99

  1. AFP: α-fetoprotein.
  2. HBsAg: hepatitis B surface antigen.
  3. *Diameter of multiple tumors was calculated as the sum of the size of every single tumor.